Recent Aspects of Cardiac Remodeling in Patients With Chronic Obstructive Pulmonary Disease

Lee, V. V.; Тимофеева, Н. И.; Задионченко, В. С.; Адашева, Т. В.; Vysotskaya, N. V.

doi:10.20996/1819-6446-2018-14-3-379-386

Cited by 4 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Согласно многочисленным исследованиям, сочетание ХОБЛ и ССЗ представляет серьезную медико-социальную проблему современного общества [7]. Некоторые исследователи утверждают, что коморбидность на фоне ХОБЛ встречается практически в 96 % случаев; кроме того, уже среди пациентов 45 лет наблюдаются случаи сочетания ХОБЛ с сопутствующим заболеванием [17]. С возрастом вероятность коморбидности стремительно увеличивается, и для пациентов 60 лет и старше в России является фактором риска для более раннего летального исхода [5].…”

Section: коморбидность хобл и ссзunclassified

“…Современная фармакологическая промышленность обеспечивает производство максимально безопасных лекарственных средств: новое поколение кардиоселективных β-адреноблокаторов. Их использование лишено в известной степени нежелательного влияния на бронхиальную проходимость при выраженной антиангинальной, антиаритмической и антигипертензивной активности, что определяет интерес врачей к этой группе препаратов [17].…”

unclassified

See 1 more Smart Citation

Comorbidity of Chronic Obstructive Pulmonary Disease and Cardiovascular Diseases: Place of Therapy with Modern β-Adrenoblockers

et al. 2019

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is the fourth largest cause of worldwide mortality. Presence of comorbidities is registered in 96% of COPD patients. The most important of these are cardiovascular diseases (coronary artery disease, arterial hypertension, chronic heart failure), which contribute to COPD patients’ mortality in every third case. COPD and cardiovascular diseases have common risk factors and pathogenesis mechanisms. Cardioselective beta-blockers reduce morbidity risk and frequency of COPD exacerbation, are effective and safe in treatment of COPD patients.

show abstract

Section: коморбидность хобл и ссзunclassified

unclassified

Comorbidity of Chronic Obstructive Pulmonary Disease and Cardiovascular Diseases: Place of Therapy with Modern β-Adrenoblockers

et al. 2019

View full text Add to dashboard Cite

show abstract

Early signs of airflow restriction and cardiovascular damage in conditionally healthy smokers

Невзорова

Kondrashova

Bogdanov

et al. 2021

Pulʹmonologiâ (Mosk.)

View full text Add to dashboard Cite

Tobacco smoking is one of the most widespread and at the same time difficult to control risk factors for chronic noncommunicable diseases, which make the most significant contribution to the mortality. Smoking intensity, development of airflow restrictions, and damage to vascular endothelium are connected to the accelerated development of atherosclerosis. At the same time, there is no evidence of a possible relationship between the development of myocardial dysfunction and exposure to tobacco combustion products. It is of interest to study the incidence of airflow restrictions, arterial hypertension, and markers of early damage to target organs - the brachiocephalic arteries (BCA) and myocardium, in so-called relatively healthy smoking individuals. The aim of the study was to describe the incidence of airflow restrictions, hypertension, the state of the brachiocephalic arteries, and indicators of global and regional longitudinal strain of the left ventricle (GLSLV and RLSLV) in actively smoking conditionally healthy individuals. Methods. 100 active smokers were examined (smoking person index or ICH > 10 (17 ± 2 packs/year)) at the mean age of 48,80± 0,68years. 55% of the patients were male. The diagnosis of COPD was made based on spirometry values before and after the test with bronchodilators (400 mcg of salbutamol) (FEV1/FVC < 70% and FEV1 increase <12% of the initial values). Blood pressure measurement, duplex scanning of brachiocephalic arteries, transthoracic echocardiography with GLSLV and RLSLV with 17-segment division by Strain method were performed in all patients. Results. COPD was diagnosed in 35% of the patients, hypertension - in 45%. Evaluation of BCA showed increased thickness of intimamedia complex in the patients with hypertension (р= 0.002) and a significantly higher degree of stenosis and number of plaques in patients with concomitant COPD and hypertension. Type 1 diastolic dysfunction of LV was detected both in patients with hypertension and in the patients with COPD, but it was most common in the patients with concomitant COPD and hypertension. The GLSLV values did not change in all patients, but the RLSLV values depended on the segment (basal, medial, apical) and were significantly lower in the patients with concomitant COPD and hypertension. Conclusion. Tobacco combustion products not only are risk factors of airflow restriction and systemic vascular dysfunction, but also cause preclinical myocardial damage, a marker of which is a violation of the longitudinal strain of the left ventricle.

show abstract

Antihypertensive therapy in patients with concomitant chronic obstructive pulmonary disease

2022

View full text Add to dashboard Cite

Objective. Evaluation of the effectiveness and safety of antihypertensive therapy with a fixed dose combination of amlodipine/indapamide in patients with hypertension (HTN) and chronic obstructive pulmonary disease (COPD).Design and methods. We conducted a non-randomized, open, single-center study, which included 74 comorbid patients (62 men, 12 women) with stage I–II HTN, grade 1–2 HTN, moderate cardiovascular risk and COPD (GOLD I–III). We also assessed respiratory function, the parameters of the microcirculatory bed, vascular stiffness, level of tumor necrosis factor α (TNF-α). For HTN, after the examination all patients were prescribed a fixed combination of amlodipine and indapamide (Arifam, Les Laboratoires Servier, France). The observation period was 6 months.Results. The study was completed by 58 patients who achieved blood pressure (BP values of 132,7 + 4,8 mm Hg), 54% patients took the initial dose of amlodipine/indapamide was 5/1,5 mg and in 46% patients, the dose of the drug was increased to 10/1,5 mg. After 6 months of treatment, a statistically significant increase in forced expiratory volume in 1st second (FEV1) was detected (p < 0,05), decrease in the average linear velocity along the maximum velocity curve (p < 0,05), Purcelo peripheral resistance index (p < 0,05), pulse wave propagation velocity in the elastic arteries, which was increased at the beginning of the study (p < 0,05), TNF-α (p < 0,05).Conclusions. The administration of a fixed combination of amlodipine/indapamide in patients with COPD and HTN leads to the achievement of target BP levels, reduction of vascular stiffness, reduction in TNF-α level, improvement of microcirculatory blood flow. The combination is safe and well-tolerated.

show abstract

Recent Aspects of Cardiac Remodeling in Patients With Chronic Obstructive Pulmonary Disease

Cited by 4 publications

References 34 publications

Comorbidity of Chronic Obstructive Pulmonary Disease and Cardiovascular Diseases: Place of Therapy with Modern β-Adrenoblockers

Comorbidity of Chronic Obstructive Pulmonary Disease and Cardiovascular Diseases: Place of Therapy with Modern β-Adrenoblockers

Early signs of airflow restriction and cardiovascular damage in conditionally healthy smokers

Antihypertensive therapy in patients with concomitant chronic obstructive pulmonary disease

Contact Info

Product

Resources

About